Sleep disorders are among the most common and disabling non-motor symptoms in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), often preceding motor symptoms by years and significantly impacting quality of life, disease progression, and caregiver burden.
Sleep disturbances in CBS and PSP differ from those in Parkinson's disease and other synucleinopathies. While rapid eye movement sleep behavior disorder (RBD) is common in synucleinopathies, CBS and PSP—predominantly 4R-tauopathies—show distinct sleep phenotypes characterized by:
The bidirectional relationship between sleep disruption and tau pathology makes sleep optimization a critical therapeutic target in these conditions[1][2].
polysomnography (PSG) studies reveal characteristic sleep architecture changes in CBS and PSP:
| Parameter | CBS | PSP | Normal |
|---|---|---|---|
| Total Sleep Time | Reduced (280-320 min) | Reduced (250-300 min) | 360-420 min |
| Sleep Efficiency | 65-75% | 60-70% | >85% |
| REM Sleep % | 8-15% | 8-12% | 20-25% |
| NREM N3 % | 10-18% | 8-15% | 15-20% |
| Sleep Latency | Prolonged (45-60 min) | Prolonged (40-55 min) | <30 min |
| REM Latency | May be normal or prolonged | Often prolonged | <90 min |
| Arousal Index | Elevated (15-25/hr) | Elevated (20-30/hr) | <10/hr |
REM Sleep Behavior Disorder in Tauopathies:
While RBD is classically associated with synucleinopathies (PD, MSA, DLB), emerging evidence shows RBD can occur in tauopathies, though less frequently. A meta-analysis found RBD in approximately 12% of PSP patients compared to 50-80% in PD[3]. The presence of RBD in a tauopathy patient may indicate:
Sleep Spindle Abnormalities:
Sleep spindles (NREM stage N2 hallmark) are reduced in both CBS and PSP, correlating with cognitive dysfunction. Reduced spindle density is associated with:
Circadian Rhythm Disruption:
PSP patients show flattened circadian rhythms with:
Prevalence: 60-80% of CBS/PSP patients
Characteristics:
Contributing Factors:
Management:
Prevalence: 30-50% of CBS/PSP patients
Characteristics:
Contributing Factors:
Management:
Prevalence: 40-60% of CBS/PSP patients
Types:
Risk Factors:
Management:
Prevalence: 10-15% in PSP (lower than synucleinopathies)
Characteristics:
Management:
Prevalence: 15-25% in CBS/PSP
Characteristics:
Management:
Characteristics:
Management:
| Assessment | Purpose | When to Order |
|---|---|---|
| Polysomnography (PSG) | Gold standard for sleep architecture, RBD, sleep apnea | Initial evaluation of sleep complaints |
| Actigraphy | 2-week sleep-wake pattern, circadian rhythm | Suspected circadian dysfunction, insomnia |
| MSLT | Daytime sleepiness, narcolepsy | Suspected excessive daytime sleepiness |
| Home Sleep Apnea Test | Screen for obstructive sleep apnea | Initial OSA screening |
History:
Physical Exam:
Laboratory Testing:
| Strategy | Implementation | Evidence |
|---|---|---|
| Consistent schedule | Same bedtime/wake time ± 30 min daily | Strong |
| Sleep environment | Cool (65-68°F), dark, quiet | Strong |
| Blue light restriction | No screens 1-2 hours before bed | Strong |
| Caffeine restriction | No caffeine after 12 PM | Strong |
| Alcohol restriction | No alcohol within 3 hours of bedtime | Moderate |
| Exercise timing | Morning/afternoon; avoid evening | Moderate |
| Bedroom use | Reserve bed for sleep only | Strong |
| Medication | Dose | Indication | Key Considerations |
|---|---|---|---|
| Melatonin | 0.5-10 mg HS | Sleep onset, circadian rhythm, RBD | First-line; antioxidant properties |
| Trazodone | 25-100 mg HS | Sleep maintenance | Lowest effective dose; monitor orthostasis |
| Gabapentin | 100-600 mg HS | Sleep, RLS, pain | May improve sleep quality |
| Medication | Dose | Indication | Key Considerations |
|---|---|---|---|
| Clonazepam | 0.25-1 mg HS | RBD | Monitor for fall risk; sedation |
| Ramelteon | 8 mg HS | Sleep onset | Hepatotoxicity risk |
| Modafinil | 100-400 mg AM | EDS | Limited evidence in CBS/PSP |
| Medication | Concern | Recommendation |
|---|---|---|
| Benzodiazepines (not clonazepam) | Fall risk, cognitive impairment | Avoid if possible |
| Zolpidem | Fall risk, complex sleep behaviors | Avoid in CBS/PSP |
| High-dose dopaminergic agents | May worsen sleep architecture | Monitor closely |
| Anticholinergics | Cognitive side effects | Avoid |
This patient is on levodopa and rasagiline (MAO-B inhibitor). Key sleep medication interactions:
| Sleep Medication | Interaction | Management |
|---|---|---|
| Clonazepam | Additive sedation | Start low; monitor for respiratory depression |
| Trazodone | Additive sedation; serotonergic effects minor | Generally safe with MAO-B inhibitors |
| Melatonin | Minimal interaction | Preferred agent |
| Gabapentin | Additive sedation | Generally safe |
| Zolpidem | Metabolized by CYP3A4; potential interaction | Use with caution |
| Time | Activity |
|---|---|
| 6:00 PM | Dinner (light, low-protein to optimize levodopa absorption) |
| 7:00 PM | Limit fluids to reduce nocturia |
| 7:30 PM | Last caffeine-free beverage |
| 8:00 PM | Gentle stretching or relaxation |
| 8:30 PM | Sleep hygiene routine begin |
| 9:00 PM | Bedroom environment preparation |
| 9:30 PM | Melatonin 1-5 mg (if indicated) |
| 9:45 PM | Bedtime |
| 10:00 PM | Lights out |
| Time | Activity |
|---|---|
| 6:30 AM | Wake time (consistent) |
| 6:45 AM | Bright light therapy 10,000 lux, 30 min |
| 7:00 AM | Breakfast |
| 7:30 AM | Physical activity (if scheduled) |
Sleep disruption may accelerate tau pathology through multiple mechanisms:
Evidence in Tauopathies:
| Factor | Rating | Notes |
|---|---|---|
| Mechanistic Rationale | 9/10 | Bidirectional relationship between sleep disruption and tau pathology is well-established |
| Evidence Level | 7/10 | Strong preclinical data; moderate clinical evidence in CBS/PSP specifically |
| Safety | 9/10 | Non-pharmacological interventions very safe; melatonin and most agents well-tolerated |
| Accessibility | 9/10 | Readily available; PSG may require referral to sleep center |
| Priority | High | Should be addressed early; impacts quality of life and potentially disease progression |
Ju YE, et al. Sleep and neurodegeneration: A bidirectional relationship. JAMA Neurol. 2024. ↩︎
Nedergaard M, et al. Glymphatic clearance of tau during sleep. Nat Neurosci. 2023. ↩︎
Iranzo A, et al. Sleep disorders in atypical parkinsonism. Sleep Med Rev. 2014. ↩︎